Eli Lilly and Company (LLY) : The value of composite uptick trades was $49.13 million, whereas, the value of composite downtick trades was $65.51 million. The uptick to downtick ratio stood at 0.75 with a negative money flow of ($16.38) Million during Thursdays trading session. The block trades money flow was negative ($15.89 million).The uptick to the downtick ratio of 0.22 in block trades signals that the large investors have utilized the rise in the stock to sell.The uptick transaction value stood at $4.58 million. The transaction of the trades on downticks amounted to $20.46 million, which confirms investors selling on the strength of price. Eli Lilly and Company (LLY) gained 121 cents at $80.57, an increase of 1.52% over the previous days close.
The stock has recorded a 20-day Moving Average of 5.23% and the 50-Day Moving Average is 6.42%. Shares have dropped -10.90% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $92.85 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $75.54 and the 200 Day Moving Average price is recorded at $76.02.
Eli Lilly and Company (NYSE:LLY): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $79.50 and $79.40 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $80.69. The buying momentum continued till the end and the stock did not give up its gains. It closed at $80.59, notching a gain of 1.55% for the day. The total traded volume was 3,823,843 . The stock had closed at $79.36 on the previous day.
In an insider trading activity, The Securities and Exchange Commission has divulged that Barnes Melissa S, officer (Chief Eth/Cmpl Ofcr & SVP, ERM) of Lilly Eli & Co, had unloaded 992 shares at an average price of $73.77 in a transaction dated on June 10, 2016. The total value of the transaction was worth $73,180.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.